Image may be NSFW.
Clik here to view.
Novo Nordisk (NYSE:NVO) today launched two new diabetes medications in pharmacies across the U.S.
The Danish company’s Ozempic product is a once-weekly GLP-1 receptor agonist designed to boost glycemic control in adults with Type II diabetes. The injection, administered in a pre-filled pen, won FDA approval in December.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk launches two new diabetes drugs in U.S. appeared first on MassDevice.
